Gara Jalqabaatti › Lymphoma Follicular › Utah › Salt Lake City
Qorannoo klinikaalii Lymphoma Follicular Salt Lake City, UT keessatti
Qorannoo 13 Lymphoma Follicular f Salt Lake City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Huntsman Cancer Institute/University of Utah, Salt Lake City
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Namoota walitti qabaa jiraSadarkaa 1
- Intermountain Healthcare, Salt Lake City
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Namoota walitti qabaa jiraSadarkaa 1/2
- Huntsman Cancer Institute, Salt Lake City
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Salt Lake City
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Namoota walitti qabaa jiraSadarkaa 3
- Huntsman Cancer Institute - Oncology Division, Salt Lake City
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Namoota walitti qabaa jiraSadarkaa 1
- Huntsman Cancer Institute/University of Utah, Salt Lake City
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Namoota walitti qabaa jiraSadarkaa 3
- Huntsman Cancer Insititute, University of Utah, Salt Lake City
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 1/2
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Namoota walitti qabaa jiraSadarkaa 2
- University of Utah, Salt Lake City
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Namoota walitti qabaa jiraSadarkaa 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Utah, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Salt Lake City
Qorannoo Lymphoma Follicular magaalota biroo keessatti
- New York City, NYQorannoo 24
- Milwaukee, WIQorannoo 19
- Nashville, TNQorannoo 18
- Houston, TXQorannoo 18
- Boston, MAQorannoo 17
- Baldwin Park, CAQorannoo 16
- Seattle, WAQorannoo 15
- Durham, NCQorannoo 15
- Columbus, OHQorannoo 13
- Chicago, ILQorannoo 12
- San Antonio, TXQorannoo 12
- Philadelphia, PAQorannoo 12
Qorannoo biroo Salt Lake City keessatti
- Kansara Qara'a Non-Small CellQorannoo 31
- Saree (Gosoota Hunda)Qorannoo 27
- Saree OljooQorannoo 27
- Kansarii ColorectalQorannoo 22
- Dhibee QaraQorannoo 21
- MelanomaQorannoo 21
- Myeloma Baay’eeQorannoo 21
- Kansara MetastatikiiQorannoo 20
- Kansarii OvariiQorannoo 19
- ObesityQorannoo 18
- Leukemia Myeloidii HamaaQorannoo 17
- Cufama OnneeQorannoo 17
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.